Nomura says Rohto earnings may top guidance on sales momentum
Nomura analysts said Rohto Pharmaceutical’s earnings for the fiscal year may beat its full-year guidance, citing strong momentum for its mainstay brands in Japan and overseas.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.